Delivery Order SPE2DB22D2206-SPE2DB25FKD06
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,438.72 to AmerisourceBergen Drug Corp for Neulasta 6 mg/0.6 ml syringes on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply transaction supporting federal medical procurement needs. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $10,026.36 for Neulasta 6 mg/0.6 mL syringes, with completion targeted for August 7, 2025. The contract, issued on August 6, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,337.32 to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits on September 12, 2025, with completion expected by September 15, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $2,337.32 to AmerisourceBergen Drug Corp for Neulasta Onpro 6 mg/0.6 ml kits, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement typical of DLA pharmaceutical procurements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical supply needs,...
- The Defense Logistics Agency awarded a $43,815.44 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Neulasta OnPro 6 mg/0.6 mL kits. The contract represents a firm fixed price, non-competitive set-aside award with an ultimate completion date of April 25, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $27,011.21 to AmerisourceBergen Drug Corp for the supply of Neulasta OnPro 6 mg/0.6 ml kits on August 29, 2025, with completion scheduled for September 2, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader relationship with the federal government. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,530.76 to AmerisourceBergen Drug Corp for Neulasta Onpro 6 mg/0.6 ml kits on September 9, 2025, with completion scheduled for September 10, 2025. The award utilized firm fixed pricing with no set-aside designation, indicating competitive selection among eligible contractors. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $43,000 to Amerisourcebergen Drug Corporation to supply NEULASTA 6 MG/0.6 ML prefilled syringes. As the prime contractor, Amerisourcebergen Drug Corporation will deliver the specified pharmaceutical product to a location in Conshohocken, Pennsylvania by September 26, 2023 under the terms of the order. The Defense Logistics Agency is the logistics combat support agency within the U.S. Department of...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,215,932 units of the pharmaceutical product NEULASTA 6 MG/0.6 ML SYRINGE 0.6ML. The order, with a potential value of $8,897.37, has a completion date of January 3, 2024. The award was made on January 2, 2024, and no set-aside designations were used. Amerisourcebergen Drug Corp, through its Corporate Office division, is an...
- Amerisourcebergen Drug Corp has been awarded a $3,705.11 firm fixed price delivery order for NEULASTA 6 MG/0.6 ML SYRINGE 0.6ML by the Defense Logistics Agency. The delivery order was awarded on October 14, 2023 under an unspecified contract vehicle and has an anticipated completion date of October 16, 2023. Place of performance will be in Conshohocken, Pennsylvania. No set-aside designation was applied to this award to supply the requested pharmaceutical product in support of Defense...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKD06Delivery Order
The Defense Logistics Agency awarded a $12,109.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Neulasta 6 mg/0.6 ml syringes on September 26, 2025, with completion scheduled for September 29, 2025. This non-set-aside contract represents a routine pharmaceutical procurement from the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, maintains a significant role in federal medical procurement through its competitive contract awards with the Defense Logistics Agency and related defense health systems. The company's federal contract portfolio demonstrates extensive capability in supplying specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. As a child contract under the DLA's broader pharmaceutical prime vendor framework, this delivery order for Neulasta—a medication used for chemotherapy-related side effects—reflects the company's ongoing role in supporting military healthcare systems, the Defense Health Agency, and other federal healthcare customers through flexible and competitively awarded contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.1k | 9/26/25 |